Related Experiment Videos
MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells
1Department of Neurology, University of Tübingen, Hoppe-Seyler-Str. 3, Tübingen, D-72076, Germany.
Abstract:
The molecular and biochemical mode of cell death of dopaminergic neurons in Parkinson's disease (PD) is uncertain. In an attempt at further clarification we studied the effects of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), on dopaminergic PC12 cells. In humans and nonhuman primates MPTP/MPP+ causes a syndrome closely resembling PD. MPP+ toxicity is thought to be mediated by the block of complex I of the mitochondrial electron transport chain. Treatment of undifferentiated PC12 cells with MPP+ primarily inhibited proliferation of PC12 cells and secondarily led to cell death after the depletion of all energy substrates by glycolysis. This cell death showed no morphological characteristics of apoptosis and was not blocked by treatment with caspase inhibitors. The inhibition of cell growth was not dependent on an inhibition of complex I activity since MPP+ also inhibited cell proliferation in SH-SY5Y cells lacking mitochondrial DNA and complex I activity (p0 cells). As shown by flow cytometric analysis, MPP+ induced a block in the G0/G1 to S phase transition that correlated with increased expression of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) and growth arrest. Since treatment with 1 microM MPP+ caused apoptotic cell death in p21(WAF1/Cip1)-deficient (p21(-/-)) but not in parental (p21(+/+)) mouse embryo fibroblasts, our data suggest that in an early phase MPP+-induced p21(WAF1/Cip1) expression leads to growth arrest and prevents apoptosis until energy depletion finally leads to a nonapoptotic cell death.
Insights
1-methyl-4-phenylpyridinium (MPP+) inhibits dopaminergic PC12 cell proliferation and causes non-apoptotic cell death by inducing p21(WAF1/Cip1) expression, preventing apoptosis until energy depletion.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Parkinson's disease (PD) pathogenesis involves dopaminergic neuron loss, but the exact cell death mechanisms remain unclear.
- 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of MPTP, is a widely used model toxin to study PD-related neurodegeneration.
- MPP+ toxicity is traditionally attributed to inhibition of mitochondrial complex I.
Purpose of the Study:
- To elucidate the molecular and biochemical mechanisms underlying MPP+-induced cell death in dopaminergic PC12 cells.
- To investigate the role of cell cycle regulation and apoptosis in MPP+-induced neurotoxicity.
- To differentiate between direct MPP+ effects and secondary consequences of energy depletion.
Main Methods:
- Treatment of PC12 cells and other cell lines (SH-SY5Y, p21(-/-) MEFs) with MPP+.
- Analysis of cell proliferation, cell death morphology, and apoptosis markers (caspase inhibitors).
- Assessment of mitochondrial function (complex I activity) and cell cycle progression (flow cytometry, p21(WAF1/Cip1) expression).
Main Results:
- MPP+ primarily inhibited PC12 cell proliferation and induced cell death after energy substrate depletion, without typical apoptotic features.
- MPP+-induced growth inhibition occurred independently of mitochondrial complex I activity.
- MPP+ caused cell cycle arrest at the G0/G1 to S phase transition, linked to increased p21(WAF1/Cip1) expression.
- In p21-deficient cells, MPP+ induced apoptosis, suggesting p21-mediated growth arrest initially prevents cell death.
Conclusions:
- MPP+ induces a dual effect: early growth arrest via p21(WAF1/Cip1) upregulation, followed by non-apoptotic cell death upon energy depletion.
- The findings challenge the sole reliance on mitochondrial complex I inhibition for MPP+ toxicity and highlight the role of cell cycle regulation in neuroprotection.
- This study provides novel insights into the complex cell death pathways relevant to Parkinson's disease.